Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Scarpa L, et al. Among authors: gruber l. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690 Clinical Trial.
68Ga-DOTATOC PET/CT in the localization of metastatic extra-adrenal paraganglioma and pheochromocytoma compared with 18F-DOPA PET/CT.
Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Jazbec T, Girod PP, Url C, Thomé C, Riechelmann H, Sprinzl GM, Fraedrich G, Virgolini IJ. Kroiss AS, et al. Among authors: gruber l. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Mar-Apr;38(2):94-99. doi: 10.1016/j.remn.2018.09.004. Epub 2019 Jan 7. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019. PMID: 30630744 English, Spanish.
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients.
Gruber L, Jiménez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, Schoenberg SO, Reindl W, Orlandi F, Mariani M, Jaschke W, Virgolini I. Gruber L, et al. J Nucl Med. 2020 Dec;61(12):1749-1755. doi: 10.2967/jnumed.119.238808. Epub 2020 Apr 24. J Nucl Med. 2020. PMID: 32332143 Free article. Clinical Trial.
Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning. A retrospective analysis.
Nilica B, Svirydenka A, Fritz J, Bayerschmidt S, Kroiss AS, Gruber L, Virgolini IJ. Nilica B, et al. Among authors: gruber l. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Aug 9:S2253-654X(21)00062-7. doi: 10.1016/j.remn.2021.03.004. Online ahead of print. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021. PMID: 34384731 English, Spanish.
297 results